Pharma Mar, S.A. (PHMMF)
USD 88.18
(-16.49%)
USD 88.18
(-16.49%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 148.54 Million EUR | -20.71% |
| 2022 | 182.7 Million EUR | -14.38% |
| 2021 | 213.39 Million EUR | -16.72% |
| 2020 | 256.24 Million EUR | 217.95% |
| 2019 | 80.59 Million EUR | -36.19% |
| 2018 | 126.29 Million EUR | -5.52% |
| 2017 | 133.66 Million EUR | -2.41% |
| 2016 | 136.97 Million EUR | -6.89% |
| 2015 | 147.1 Million EUR | 29.16% |
| 2014 | 113.9 Million EUR | 6.49% |
| 2013 | 106.95 Million EUR | 5.03% |
| 2012 | 101.83 Million EUR | -9.45% |
| 2011 | 112.46 Million EUR | 4.62% |
| 2010 | 107.49 Million EUR | 35.32% |
| 2009 | 79.43 Million EUR | 20.05% |
| 2008 | 66.17 Million EUR | 40.07% |
| 2007 | 47.24 Million EUR | 10.29% |
| 2006 | 42.83 Million EUR | 252.66% |
| 2005 | -28.05 Million EUR | -4294.17% |
| 2004 | 669 Thousand EUR | -98.4% |
| 2003 | 41.79 Million EUR | 27.12% |
| 2002 | 32.87 Million EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 36.2 Million EUR | -4.88% |
| 2024 Q3 | 43.64 Million EUR | 9.73% |
| 2024 Q2 | 39.77 Million EUR | 9.88% |
| 2023 FY | 144.86 Million EUR | -20.71% |
| 2023 Q4 | 38.06 Million EUR | 10.93% |
| 2023 Q3 | 34.3 Million EUR | -22.59% |
| 2023 Q2 | 44.32 Million EUR | 39.16% |
| 2023 Q1 | 31.85 Million EUR | -34.62% |
| 2022 FY | 182.7 Million EUR | -14.38% |
| 2022 Q1 | 49.39 Million EUR | -38.79% |
| 2022 Q2 | 44.6 Million EUR | -9.7% |
| 2022 Q4 | 48.71 Million EUR | 21.95% |
| 2022 Q3 | 39.94 Million EUR | -10.45% |
| 2021 Q3 | 41.61 Million EUR | -9.02% |
| 2021 FY | 213.39 Million EUR | -16.72% |
| 2021 Q1 | 45.32 Million EUR | 4.59% |
| 2021 Q2 | 45.74 Million EUR | 0.91% |
| 2021 Q4 | 80.7 Million EUR | 93.91% |
| 2020 FY | 256.24 Million EUR | 217.95% |
| 2020 Q1 | 97.39 Million EUR | 341.24% |
| 2020 Q3 | 47.64 Million EUR | -29.78% |
| 2020 Q4 | 43.33 Million EUR | -9.05% |
| 2020 Q2 | 67.86 Million EUR | -30.32% |
| 2019 Q2 | 20.66 Million EUR | 13.9% |
| 2019 Q4 | 22.07 Million EUR | 12.02% |
| 2019 Q1 | 18.14 Million EUR | -18.18% |
| 2019 Q3 | 19.7 Million EUR | -4.66% |
| 2019 FY | 80.59 Million EUR | -36.19% |
| 2018 Q1 | 33.74 Million EUR | 9.13% |
| 2018 Q4 | 22.17 Million EUR | -1.83% |
| 2018 Q2 | 47.78 Million EUR | 41.6% |
| 2018 Q3 | 22.59 Million EUR | -52.72% |
| 2018 FY | 126.29 Million EUR | -5.52% |
| 2017 Q1 | 34.32 Million EUR | 2.03% |
| 2017 Q4 | 30.92 Million EUR | -2.98% |
| 2017 FY | 133.66 Million EUR | -2.41% |
| 2017 Q3 | 31.87 Million EUR | -12.79% |
| 2017 Q2 | 36.54 Million EUR | 6.46% |
| 2016 Q4 | 33.64 Million EUR | -5.41% |
| 2016 FY | 136.97 Million EUR | -6.89% |
| 2016 Q2 | 36.02 Million EUR | 13.56% |
| 2016 Q3 | 35.57 Million EUR | -1.27% |
| 2016 Q1 | 31.72 Million EUR | -41.16% |
| 2015 Q1 | 27.37 Million EUR | 5.2% |
| 2015 FY | 147.1 Million EUR | 29.16% |
| 2015 Q4 | 53.91 Million EUR | 79.84% |
| 2015 Q3 | 29.98 Million EUR | -16.34% |
| 2015 Q2 | 35.83 Million EUR | 30.92% |
| 2014 Q4 | 26.02 Million EUR | -10.24% |
| 2014 FY | 113.9 Million EUR | 6.49% |
| 2014 Q3 | 28.99 Million EUR | -8.98% |
| 2014 Q2 | 31.85 Million EUR | 17.8% |
| 2014 Q1 | 27.03 Million EUR | 6.67% |
| 2013 Q3 | 28.13 Million EUR | -4.92% |
| 2013 Q4 | 25.34 Million EUR | -9.91% |
| 2013 FY | 106.95 Million EUR | 5.03% |
| 2013 Q1 | 23.88 Million EUR | -52.49% |
| 2013 Q2 | 29.59 Million EUR | 23.88% |
| 2012 Q3 | 26.04 Million EUR | -8.35% |
| 2012 FY | 101.83 Million EUR | -9.45% |
| 2012 Q1 | 24.04 Million EUR | -56.08% |
| 2012 Q2 | 28.41 Million EUR | 18.18% |
| 2012 Q4 | 50.27 Million EUR | 93.08% |
| 2011 Q1 | 25.31 Million EUR | 7.26% |
| 2011 Q4 | 54.74 Million EUR | 92.95% |
| 2011 FY | 112.46 Million EUR | 4.62% |
| 2011 Q3 | 28.37 Million EUR | -10.9% |
| 2011 Q2 | 31.84 Million EUR | 25.77% |
| 2010 Q1 | 24.34 Million EUR | 44.74% |
| 2010 Q2 | 30.53 Million EUR | 25.45% |
| 2010 FY | 107.49 Million EUR | 35.32% |
| 2010 Q3 | 29.01 Million EUR | -4.99% |
| 2010 Q4 | 23.6 Million EUR | -18.65% |
| 2009 Q3 | 21.84 Million EUR | -14.55% |
| 2009 Q1 | 15.21 Million EUR | -2.81% |
| 2009 Q2 | 25.56 Million EUR | 68.02% |
| 2009 FY | 79.43 Million EUR | 20.05% |
| 2009 Q4 | 16.81 Million EUR | -23.01% |
| 2008 Q4 | 15.65 Million EUR | -5.97% |
| 2008 Q3 | 16.64 Million EUR | -17.3% |
| 2008 Q2 | 20.13 Million EUR | 46.52% |
| 2008 Q1 | 13.73 Million EUR | 0.0% |
| 2008 FY | 66.17 Million EUR | 40.07% |
| 2007 FY | 47.24 Million EUR | 10.29% |
| 2006 FY | 42.83 Million EUR | 252.66% |
| 2005 FY | -28.05 Million EUR | -4294.17% |
| 2004 FY | 669 Thousand EUR | -98.4% |
| 2003 FY | 41.79 Million EUR | 27.12% |
| 2002 FY | 32.87 Million EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Bioxytran, Inc. | -8285.00 USD | 1792978.696% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | -890.333% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | -1416.643% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -225891.967% |
| Evofem Biosciences, Inc. | 11.7 Million USD | -1168.922% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | -24.711% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 435063.397% |
| Marizyme, Inc. | 457.7 Thousand USD | -32353.43% |
| Genus plc | 178.7 Million USD | 16.877% |
| Pharming Group N.V. | 220.1 Million USD | 32.514% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -238610.507% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -36114.694% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 1350463.636% |
| ContraFect Corporation | -154 Thousand USD | 96554.545% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -193409.725% |
| IMV Inc. | -962.29 Thousand USD | 15535.967% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 38432.804% |
| ONE Bio Corp. | 20.12 Million USD | -638.071% |
| RVL Pharmaceuticals plc | 40.26 Million USD | -268.906% |
| Mesoblast Limited | -35.16 Million USD | 522.373% |
| MultiCell Technologies, Inc. | 49.32 USD | -301175893.512% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | -425.712% |
| Genscript Biotech Corporation | 409.55 Million USD | 63.731% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -4788423.533% |
| Biomind Labs Inc. | -15.42 Thousand USD | 963144.606% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 13111.882% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -212100.0% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 119648.334% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 2999696.123% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 297180.0% |
| Arch Therapeutics, Inc. | -2439.00 USD | 6090300.902% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -105622.42% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -303662.781% |
| Q BioMed Inc. | -8988.00 USD | 1652747.975% |
| GB Sciences, Inc. | -624.00 USD | 23804587.179% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 172764.714% |
| CSL Limited | 7.56 Billion USD | 98.035% |
| Agentix Corp. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | -234.868% |
| Enzolytics Inc. | 30.7 Thousand USD | -483617.598% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | -30689.768% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 152425.283% |
| argenx SE | 1.1 Billion USD | 86.6% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 675.781% |
| HST Global, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 71413561.538% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 28970.187% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 1677380.939% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -23959.58% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 177251.785% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | -14934.702% |
| Capstone Therapeutics Corp. | 9.61 Million USD | -1445.521% |
| Kadimastem Ltd | -630.13 Thousand USD | 23672.614% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.42 Million USD | -862.992% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 1255190.832% |
| Cell Source, Inc. | - USD | -Infinity% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 307897.509% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -84030.041% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -84030.041% |
| Affymax, Inc. | 1.35 Million USD | -10845.051% |
| Mobile Lads Corp. | - USD | -Infinity% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | -3123.524% |
| CytoDyn Inc. | -29 Thousand USD | 512306.897% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | -32905.735% |
| SYBLEU INC | 11.69 Thousand USD | -1269906.84% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 46590.374% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 39923.056% |
| Neutra Corp. | 14.33 Thousand USD | -1036105.092% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 181246.341% |
| PureTech Health plc | -1.6 Million USD | 9366.376% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 14935.663% |
| IXICO plc | 3.27 Million USD | -4442.508% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 21503.458% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 8393.691% |
| CSL Limited | 7.7 Billion USD | 98.072% |
| Cellectis S.A. | 18 Thousand USD | -825122.222% |